Skip to main content

Home/ Nutrition/ Group items tagged treatment

Rss Feed Group items tagged

Vaughn Tobes

Fatty Liver Treatment - 0 views

  •  
    What is the best fatty liver treatment, and what are the options available today? Aside from what you may have been told from a doctor, natural and safe treatments already exist that have been eliminating Fatty Liver Disease for thousands of people, without the need for expensive medications or surgeries.
Vaughn Tobes

Cure Fatty Liver Disease Naturally with The Fatty Liver Solution - 0 views

  •  
    Natural Fatty Liver Treatment Reverses and Cures Fatty Liver Disease
Vaughn Tobes

The Fatty Liver Solution Reverses, Cures Fatty Liver Disease - 0 views

  •  
    The All Natural Treatment Effectively Eliminates Fatty Liver Disease
Vaughn Tobes

More Fatty Liver Patients Find Success Using the Fatty Liver Solution - 0 views

  •  
    Eliminate Fatty Liver Disease with the Fatty Liver Solution
Vaughn Tobes

Fatty Liver Disease Diets and Treatments - Fatty Liver Diet Plans.com - 0 views

  •  
    Fatty Liver diet plans and fatty liver treatments to cure Fatty Liver Disease.
Matti Narkia

Artemisinin - Wikipedia, the free encyclopedia - 0 views

  •  
    Artemisinin (pronounced /ɑːtə'misinən/) is a drug used to treat multi-drug resistant strains of falciparum malaria. The compound (a sesquiterpene lactone) is isolated from the plant Artemisia annua. Not all plants of this species contain artemisinin. Apparently it is only produced when the plant is subjected to certain conditions, most likely biotic or abiotic stress. It can be synthesized from artemisinic acid.[1] The drug is derived from a herb used in Chinese traditional medicine, though it is usually chemically modified and combined with other medications.

    Artemisinin is under early research and testing for treatment of cancer, primarily by researchers at the University of Washington.[7][8] Artemisinin has a peroxide lactone group in its structure. It is thought that when the peroxide comes into contact with high iron concentrations (common in cancerous cells), the molecule becomes unstable and releases reactive oxygen species. It has been shown to reduce angiogenesis and the expression of vascular endothelial growth factor in some tissue cultures.
Matti Narkia

Sloan-Kettering - Integrative Medicine - 0 views

  •  
    The Integrative Medicine Service at Memorial Sloan-Kettering Cancer Center was established in 1999 to complement mainstream medical care and address the emotional, social, and spiritual needs of patients and families. The Service includes:

    patient and outpatient clinical care
    research, and education and training.

    In addition, the Service provides unique access to otherwise unavailable information about over-the-counter products and unproven cancer treatments and their impact in the context of cancer care via our About Herbs database
Matti Narkia

Are omega-3 fatty acids options for prevention and treatment of cognitive decline and d... - 0 views

  •  
    Are omega-3 fatty acids options for prevention and treatment of cognitive decline and dementia?
    Cederholm T, Palmblad J.
    Curr Opin Clin Nutr Metab Care. 2009 Dec 16. [Epub ahead of print]
    PMID: 20019606

    PURPOSE OF REVIEW: To report recent data on the potential role of omega-3 fatty acids (n-3 FA) found in oily fish, especially docosahexaenoic acid (DHA), to prevent and treat cognitive decline and Alzheimer's disease. RECENT FINDINGS: Observational studies still provide conflicting results, in which the majority indicate beneficial effects on cognition, both when assessed as a continuous variable or as incident dementia, mainly Alzheimer's disease. Experimental studies have demonstrated potentially ameliorating effects of eicosapentaenoic acid (EPA) and DHA on amyloid fragment formation, signal transduction including upregulation of the apolipoprotein receptor SorLA, as well as on angiogenesis. The role of EPA and DHA metabolites on Alzheimer's disease pathology is under investigation. Recently, three randomized intervention studies, with duration up to 6 months have been reported. In contrast to a small study from Taiwan, no positive overall effects were reported from the Swedish OmegAD Study or from a Dutch study, although post hoc analyses indicate that selected individuals with mild forms of Alzheimer's disease or cognitive decline may respond to treatment. SUMMARY: No firm conclusions can be drawn. Based on epidemiological data, fish including oily fish could be advised as part of a balanced diet for public health purpose, although the evidence for better cognition is only fairly consistent. It is unlikely that n-3 FA will emerge as a treatment option in general for improving cognitive function in patients with Alzheimer's disease. n-3 FA, especially DHA, may turn out as an adjuvant therapy in selected cases. Further long-term intervention studies on individuals with mild cognitive reductions are awaite"
Matti Narkia

Diagnosis and treatment of vitamin D deficiency; Expert Opinion on Pharmacotherapy - 9(... - 0 views

  •  
    Diagnosis and treatment of vitamin D deficiency.
    Cannell JJ, Hollis BW, Zasloff M, Heaney RP.
    Expert Opin Pharmacother. 2008 Jan;9(1):107-18.
    PMID: 18076342

    The recent discovery - in a randomised, controlled trial - that daily ingestion of 1100 IU of colecalciferol (vitamin D) over a 4-year period dramatically reduced the incidence of non-skin cancers makes it difficult to overstate the potential medical, social and economic implications of treating vitamin D deficiency. Not only are such deficiencies common, probably the rule, vitamin D deficiency stands implicated in a host of diseases other than cancer. The metabolic product of vitamin D is a potent, pleiotropic, repair and maintenance, secosteroid hormone that targets > 200 human genes in a wide variety of tissues, meaning it has as many mechanisms of action as genes it targets. A common misconception is that government agencies designed present intake recommendations to prevent or treat vitamin D deficiency. They did not. Instead, they are guidelines to prevent particular metabolic bone diseases. Official recommendations were never designed and are not effective in preventing or treating vitamin D deficiency and in no way limit the freedom of the physician - or responsibility - to do so. At this time, assessing serum 25-hydroxy-vitamin D is the only way to make the diagnosis and to assure that treatment is adequate and safe. The authors believe that treatment should be sufficient to maintain levels found in humans living naturally in a sun-rich environment, that is, > 40 ng/ml, year around. Three treatment modalities exist: sunlight, artificial ultraviolet B radiation or supplementation. All treatment modalities have their potential risks and benefits. Benefits of all treatment modalities outweigh potential risks and greatly outweigh the risk of no treatment. As a prolonged 'vitamin D winter', centred on the winter solstice, occurs at many temperate latitudes, ≤ 5000 IU (125 μg) of vitamin D/d
Matti Narkia

Role of vitamin K2 in the treatment of postmenopausal osteoporosis. - Curr Drug Saf. 20... - 0 views

  •  
    Role of vitamin K2 in the treatment of postmenopausal osteoporosis.
    Iwamoto J, Takeda T, Sato Y.
    Curr Drug Saf. 2006 Jan;1(1):87-97. Review.
    PMID: 18690918
Matti Narkia

Vitamin D for cancer prevention: global perspective. Garland CF et al. -Ann Epidemiol. ... - 0 views

  •  
    Vitamin D for cancer prevention: global perspective.
    Garland CF, Gorham ED, Mohr SB, Garland FC.
    Ann Epidemiol. 2009 Jul;19(7):468-83. Review.
    PMID: 19523595
Matti Narkia

Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine... - 0 views

  •  
    Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine.
    Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, Huo L, Wang M, Hong J, Wu P, Ren G, Ning G.
    J Clin Endocrinol Metab. 2008 Jul;93(7):2559-65. Epub 2008 Apr 8.
    PMID: 18397984
    doi:10.1210/jc.2007-2404

    Conclusions: Berberine is effective and safe in the treatment of type 2 diabetes and dyslipidemia.
Matti Narkia

Effect of glucosamine sulfate with or without omega-3 fatty acids in patients with oste... - 0 views

  •  
    Effect of glucosamine sulfate with or without omega-3 fatty acids in patients with osteoarthritis.
    Gruenwald J, Petzold E, Busch R, Petzold HP, Graubaum HJ.
    Adv Ther. 2009 Sep 4. [Epub ahead of print]
    PMID: 19756416
    DOI: 10.1007/s12325-009-0060-3
Matti Narkia

Omega-3 fatty acids boost glucosamine's arthritis benefit - Life Extension Update - 0 views

  •  
    "In the September 2009 issue of the journal Advances in Therapy, German researchers report that the addition of omega-3 polyunsaturated fatty acids to the over-the-counter arthritis treatment glucosamine sulfate resulted in improved alleviation of symptoms compared to glucosamine alone. The trial is the first, to the authors' knowledge, to test the combination in patients with osteoarthritis.

    In their introduction to the article, Joerg Gruenwald and his coauthors explain that a chronic imbalance between the synthesis and degradation of cartilage matrix leads to the loss of joint tissue that occurs in osteoarthritis. Glucosamine and omega-3 fatty acids appear to be successful in adjusting this imbalance in the direction of new cartilage synthesis"
Matti Narkia

Correlation of symptoms with vitamin D deficiency and symptom response to cholecalcifer... - 0 views

  •  
    Correlation of symptoms with vitamin D deficiency and symptom response to cholecalciferol treatment: a randomized controlled trial.
    Arvold DS, Odean MJ, Dornfeld MP, Regal RR, Arvold JG, Karwoski GC, Mast DJ, Sanford PB, Sjoberg RJ.
    Endocr Pract. 2009 May-Jun;15(3):203-12.
    PMID: 19364687

    Conclusions: Compared with participants in the placebo group, patients in the treatment group showed mild short-term improvement in the overall fibromyalgia impact score, but did not show significant improvement in most musculoskeletal symptoms or in activities of daily living.
Matti Narkia

Multiple Sclerosis and You - Multiple Sclerosis (MS) Symptoms, Diagnosis and Treatments... - 0 views

  •  
    Multiple Sclerosis Blog
    By Julie Stachowiak, Ph.D.,
Matti Narkia

High doses of vitamin D could cut relapse rate among MS sufferers - Times Online - 0 views

  •  
    "Powerful new evidence about the ability of vitamin D to stem a wide range of diseases has brought the prospect of a nationwide programme to prescribe it in Scotland as a dietary supplement significantly closer.

    Reports at the weekend suggested that experts were increasingly convinced that the so-called sunshine drug - whose significance was first revealed in detail by The Times last year - could make a difference to the country's appalling health record.

    New research suggests that high doses of vitamin D could dramatically cut the relapse rate in people with multiple sclerosis. According to scientists in Canada, more than a third of sufferers taking high levels of supplement
Matti Narkia

Vegan Diet May Treat Diabetes - CBS News - 0 views

  •  
    "(WebMD) Eating a low-fat vegan diet may be better at managing type 2 diabetes than traditional diets, according to a new study.

    Researchers found 43 percent of people with type 2 diabetes who followed a low-fat vegan diet for 22 weeks reduced their need to take medications to manage their disease compared with 26 percent of those who followed the diet recommended by the American Diabetes Association (ADA).

    In addition, participants who followed the vegan diet experienced greater reductions in cholesterol levels and weight loss than those on the other diet."
Matti Narkia

Vitamin D and MS: Burton - 0 views

  •  
    "Dr. Jodie Burton is the acting principal investigator (PI) of the dose-escalation trial of oral vitamin D3 with calcium supplementation in patients with multiple sclerosis with Dr. O'Connor. She started the trial as his fellow, while doing an additional 2 years of training in MS specifically after she received her neurology certification. She completed her fellowship training in 2007. Now she is staff doing clinical research and continuing with the vitamin D trial. As of August 2009, she will be Assistant Professor in Neurology in the Department of Clinical Neuroscience in Calgary and at the University of Calgary. She will be part of the MS team there with Dr. Luanne Metz and the MS group.

    Please scroll down for an abstract of the trial:
    A Phase I/II dose-escalation trial of oral vitamin D3 with calcium supplementation in patients with multiple sclerosis."

    Conclusions:
    High-dose VD3 (~10 000 IU/day, possibly higher) in MS is safe and tolerable, with evidence of clinical improvement."
1 - 20 of 105 Next › Last »
Showing 20 items per page